About
Irinotecan is a topoisomerase I inhibitor, a prodrug converted to its active metabolite SN-38, which binds to the topoisomerase I-DNA complex, preventing religation of DNA single-strand breaks. This leads to accumulation of DNA damage and ultimately apoptosis in rapidly proliferating cells. It is a key component in the treatment of metastatic colorectal cancer and other solid tumors. Its efficacy stems from its ability to interfere with DNA replication and transcription, making it a potent cytotoxic agent.
Irinotecan's metabolism involves hepatic carboxylesterases for activation and UGT1A1 for detoxification of SN-38. Genetic polymorphisms in UGT1A1 can significantly impact drug clearance and toxicity, particularly severe neutropenia and diarrhea. Careful patient selection and monitoring are crucial to manage its dose-limiting toxicities. It is administered intravenously, often as part of combination chemotherapy regimens.
Uses
- Treatment of metastatic colorectal cancer
- Management of advanced pancreatic cancer
- Therapy for certain gastric cancers
- Used in combination regimens for solid tumors
Directions For Use
Administer intravenously over 30 to 90 minutes. Dosage and schedule are determined by a physician based on the specific cancer type and patient's condition.
Benefits
- Effective against advanced colorectal cancer
- Can improve survival in metastatic disease
- Part of established combination chemotherapy regimens
- Offers a distinct mechanism of action
- May be used in refractory cases
- Contributes to disease control
Side Effects
- Severe diarrhea (early and late onset)
- Myelosuppression (neutropenia, anemia)
- Nausea and vomiting
- Abdominal cramps
- Cholinergic syndrome (acute)
- Fatigue and asthenia
- Alopecia (hair loss)
- Fever
- Dehydration
- Mucositis
- Elevated liver enzymes
- Infection risk
Safety Measures
- Alcohol - Avoid alcohol during irinotecan treatment as it may exacerbate gastrointestinal side effects, particularly diarrhea, and could potentially interact with drug metabolism.
- Pregnancy - Irinotecan is contraindicated in pregnancy due to its genotoxic and teratogenic potential. Women of childbearing potential must use effective contraception during and for a period after treatment.
- Breastfeeding - Breastfeeding is contraindicated during irinotecan treatment due to the potential for serious adverse reactions in the breastfed infant.
- Liver - Use with caution in patients with pre-existing liver impairment. Monitor liver function tests closely, especially bilirubin levels, as hepatic dysfunction can increase SN-38 exposure and toxicity.
- Kidney - Irinotecan and its metabolites are partially excreted renally. Use with caution in patients with renal impairment, and monitor kidney function. Dose adjustments may be considered in severe cases.
- Lung - Interstitial lung disease is a rare but serious adverse event. Monitor patients for new or worsening pulmonary symptoms, such as dyspnea or cough.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!